Cone Opsin-GIRK Gene Therapy for Light-Sensitive RCD Cones
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for rod-cone dystrophy (RCD) are limited by the variability of mutations and cannot effectively treat dominant mutations or patients with unknown causative mutations, and existing optogenetic strategies face challenges such as immunogenicity and low light sensitivity of microbial opsins.
Innovation Solution
A gene therapy approach using a vector encoding a mutated form of the G-protein-gated inwardly rectifying potassium channel (GIRK1 F137S) and mammalian cone opsin, activated by G proteins, is introduced to reactivate the phototransduction cascade in degenerating cones, enhancing light sensitivity and color vision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If microbial opsins are used in optogenetic strategies, then light sensitivity can be restored, but immunogenicity and low light sensitivity occur
Solution Approach 1:
The patent uses human cone opsin (endogenous protein) instead of microbial opsin to restore light sensitivity. This copying approach uses the patient's own native protein sequence, eliminating immunogenicity while maintaining the phototransduction function. The GIRK1 F137S channel is paired with the patient's endogenous cone opsin to recreate the natural phototransduction cascade without introducing foreign proteins.
Solution Approach 2:
The patent modifies the GIRK1 channel by introducing the F137S mutation, which changes the channel's biophysical properties to enable proper coupling with cone opsin and G-proteins. This parameter change in the channel protein allows it to respond appropriately to opsin activation, achieving enhanced light sensitivity with low light intensities while using endogenous proteins to avoid immune responses.
2Measurement precision
If gene therapy approaches target specific mutations, then treatment precision can be improved, but variability of mutations and unknown causative mutations cannot be effectively treated
Solution Approach 1:
The patent employs a universal approach by using the patient's endogenous cone opsin gene sequence paired with the GIRK1 F137S channel. This combination works across different RCD mutations because it relies on the conserved cone opsin-G-protein-GIRK signaling pathway rather than targeting specific mutation sites. The therapy can be applied to patients with various causative mutations including those with unknown genetic causes, as it restores the downstream phototransduction cascade that is commonly disrupted in RCD.
3Use of energy by moving object
If conventional phototransduction cascade is used, then light signal transduction can occur, but the cascade becomes deactivated requiring transducin and phosphodiesterase 6 which are lost in advanced RCD
Solution Approach 1:
The patent extracts and eliminates the problematic components of the conventional phototransduction cascade (transducin and phosphodiesterase 6) that are lost or dysfunctional in advanced RCD. Instead, it uses a simplified alternative pathway where cone opsin directly activates G-proteins (Gαi/o) that gate GIRK1 F137S channels. This extracted pathway removes the dependency on the degraded conventional cascade components while maintaining light signal transduction capability.
Solution Approach 2:
The GIRK1 F137S channel acts as an intermediary that bridges cone opsin activation and the electrical response needed for vision. Rather than relying on the conventional cGMP-PDE-CNG channel pathway, the GIRK channel provides an alternative intermediary mechanism that couples opsin-G-protein activation directly to potassium channel gating, enabling light signal transduction without the lost conventional cascade components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach restores and maintains high acuity and color vision in RCD patients by hyperpolarizing cones with low light intensities, even in advanced stages of the disease, using a vector like AAV to deliver GIRK1 F137S and cone opsin.
Implementation Method 1
The light sensitive G protein coupled receptors that link photon capture to intracellular signaling leading to membrane hyperpolarization in photoreceptors are called opsins
Implementation Method 2
G-protein-gated-K+ channel (GIRK), in particular GIRK1 F137S, activated by G proteins recruited by cone opsin expressed in degenerating cones
Data Source
AI summary
The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK1 F137S, activated by G proteins recruited by cone opsin expressed in degenerating cones.